NCT04041128 is a EARLY_PHASE1 clinical trial of Lynparza in Ovarian Cancer, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT04041128?

NCT04041128 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT04041128?

Interventions in NCT04041128: Lynparza.

What condition does NCT04041128 study?

NCT04041128 studies Ovarian Cancer, Breast Cancer.

Is NCT04041128 still recruiting?

NCT04041128 is currently completed. Last updated 20 March 2023.

Last reviewed 2023-03-20 · How we verify

NCT04041128

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

Completed EARLY_PHASE1 Last updated 20 March 2023

What this trial tests

EARLY_PHASE1 trial testing Lynparza in Ovarian Cancer in 14 participants. Completed in 15 June 2021.

Timeline

23 July 2019

Primary endpoint
15 June 2021

15 June 2021

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	14
Start date	23 July 2019
Primary completion	15 June 2021
Estimated completion	15 June 2021
Sites	1 location across United States

Drugs / interventions tested

Lynparza — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

University of Texas Southwestern Medical Center

Who can join

Adults 18 to 99, female only, with Ovarian Cancer or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study involves surgery for cytoreduction or laparoscopy to determine if you are a candidate for tumor debulking or a tissue biopsy. Following this surgery you will receive chemotherapy. This study will administer 7 days of treatment with a targeted therapy called Lynparza. Lynparza and/or other PARP inhibitors have been FDA approved for the treatment of ovarian and breast cancer. Tissue biopsy will be done before a 7 day course of Lynparza in order to correlate molecular changes to response to treatment. Participation in this trial will require an additional tumor biopsy which will occur either before or after treatment of Lynparza.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M, Chen S, Ao D. · · 2021 · cited 84× · PMID 34977872 · DOI 10.1002/mco2.103
PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Gonçalves A, Bertucci A, Bertucci F. · · 2020 · cited 26× · PMID 32471249 · DOI 10.3390/cancers12061378
DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1.
Srivastava R, Srivastava R, Lodhi N. · · 2022 · cited 15× · PMID 35327610 · DOI 10.3390/biom12030417
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W, Rajendran BK, Cui T, Sun J, et al · · 2025 · cited 3× · PMID 39450552 · DOI 10.3892/ijmm.2024.5447
Saying "Yes" to NONO: A Therapeutic Target for Neuroblastoma and Beyond.
Pogodaeva SS, Miletina OO, Antipova NV, Shtil AA, et al · · 2025 · cited 2× · PMID 41097754 · DOI 10.3390/cancers17193228

Verify or expand the search:

Other trials of Lynparza

Trials testing the same drug.

NCT05081765 — The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib · unknown

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04041128 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 20 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04041128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing